Cancer Stories
Didn't see your exact story?
Search by cancer type, stage, biomarker or treatment to find people who've been exactly where you are.
Discuss
PatientSavvy: Join us
Cancer Stories
Search by cancer type, stage, biomarker or treatment to find people who've been exactly where you are.
Discuss
PatientSavvy: Join us
8 stories match lung cancer and ipilimumab. 6 of them mention chemotherapy.
Cancer Stories
Lung CancerPatient Info: Anonymized, Male | Stage IV
Biomarkers: Cancer biomarkers not reported. Thyroid storm workup had TSAb/TRAb positivity consistent with Graves disease.
Metastatic Site: not specified in extracted case text
Lung CancerStage IVB lung adenocarcinoma with severe immune-related complications
Patient Info: Anonymized, Male, 70+ | Stage IV
Biomarkers: PD-L1 TPS 20%; BRAF mutation
Metastatic Site: left supraclavicular fossa, left axilla, right hilum,…
Lung CancerStage 4 lung cancer: large tumor managed with targeted care
Patient Info: Anonymized, Male, 70+ | Stage IV
Biomarkers: PD-L1 TPS <1%
Metastatic Site: contralateral lymph nodes, supraclavicular lymph…
Lung CancerTwo Severe Kidney Injuries After Lung Cancer Immunotherapy
Patient Info: Anonymized, Male, 70+
Lung CancerStage IV PD-L1-negative lung adenocarcinoma: complete response with nivolumab and ipilimumab
Patient Info: Anonymized, Female, 50s | Stage IV
Biomarkers: PD-L1-negative; no targetable molecular alterations on DNA/RNA next-generation sequencing; TP53 alteration reported at 66%
Metastatic Site: left pleural effusion; right adrenal gland;…
Lung CancerTreatment-related lung injury during therapy for Stage IV squamous lung cancer
Patient Info: Anonymized, Male, 60s | Stage IV
Lung CancerFatal lung-cancer progression after immune-related HLH during nivolumab and ipilimumab
Patient Info: Anonymized, male, 40s | Stage IV
Metastatic Site: pleura, lung
Lung CancerStage IV lung adenocarcinoma complicated by immunotherapy-related perimyocarditis
Patient Info: Anonymized, female, 70+ | Stage IV
Biomarkers: EGFR-negative; ALK-negative; ROS1-negative; PD-L1 <1%